SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG Outcome study

Nursing and Health Professions

• Patient 100%
• Empagliflozin 62%
• Cardiovascular Mortality 50%
• Diseases 37%
• Hospitalization 37%
• Heart Failure 25%
• Blood Pressure 25%
• Heart Infarction 25%
• Sodium Glucose Cotransporter 2 Inhibitor 25%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 25%
• Non Insulin Dependent Diabetes Mellitus 12%
• Cardiovascular Risk 12%
• Glucose Blood Level 12%
• Body Weight 12%
• Cause of Death 12%
• Cardiovascular Disease 12%
• Hemoglobin A1c 12%
• Major Adverse Cardiac Event 12%
• Volume 12%
• Death 12%

Medicine and Dentistry

• Empagliflozin 62%
• Type 2 Diabetes 50%
• Cardiovascular Mortality 50%
• Diseases 37%
• Cardiovascular System 25%
• Heart Failure 25%
• Maturity Onset Diabetes of the Young 25%
• Blood Pressure 25%
• Myocardial Infarction 25%
• Sodium Glucose Cotransporter 2 Inhibitor 25%
• Apoplexy 25%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 25%
• Body Weight 12%
• Hemoglobin A1c 12%
• High Density Lipoprotein Cholesterol 12%
• Cardiovascular Disease 12%
• Cardiovascular Risk 12%
• Cause of Death 12%
• Unstable Angina Pectoris 12%
• Major Adverse Cardiac Event 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Empagliflozin 62%
• Cardiovascular Mortality 50%
• Diseases 37%
• Non Insulin Dependent Diabetes Mellitus 25%
• Heart Infarction 25%
• Heart Failure 25%
• Sodium Glucose Cotransporter 2 Inhibitor 25%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 25%
• High Density Lipoprotein Cholesterol 12%
• Cardiovascular Risk 12%
• Unstable Angina Pectoris 12%
• Cause of Death 12%
• Major Adverse Cardiac Event 12%
• Hemoglobin A1c 12%
• Death 12%